SUN Pharma :

- Indepth research, own manufacturing facility, deep marketing network made sun pharma a big success in Indian Market.
- Took 27 years to reach US$ 1 Billion reenue
- Next 3 years next 1 Billion $ revenue trickled in.
- This buge growth is due to strong foundation SUN Pharma laid over years to penetrate regulated drug markets in US and Europe.
- Acqusitions : in 1997, acquired Caraco Pharma. In 2010 acquired TARO Pharma of Israel. Acquired Dusa pharma in 2012. Acquired the generic business of URL Pharma in 2013.
- JV with Merck in 2011
- In total, SUN acquired 16 companies which had higher potential but were underperforming.
- Almost Debt Free : Debt equity ratio @ 0.03 in FY 2012.
- 26 manufacturing facilities in India, US, Canada, Brazil, Mexico, Hungary, Israel and Bangladesh.
- 70% revenue from international Markets.
- Recent setback - New Jersy court has slapped a fine of US$ 550 million on patent infringement of Protoix - an anti acid reflux drug owned by Pfizer. This is a significant hit on US$ 1.3 billion SUN had for prospective takeovers.
- Expects to grow by 18% to 20% in FY 2014.